Group 1 - On July 15, A-shares showed mixed performance with the Shanghai Composite Index down 0.42% at 3505 points, while the Shenzhen Component Index rose 0.56% to 10744.56 points, and the ChiNext Index increased by 1.73% to 2235.05 points [1] - In the past 30 days, there have been changes in 432 fund managers across various fund products, indicating potential impacts on future fund performance [1] - On July 15, 9 fund products announced fund manager departures, with reasons including job changes and product expirations [1] Group 2 - The largest fund manager by asset size is Zhang Xiaonan from Invesco Great Wall Fund, managing assets totaling 34.159 billion yuan, primarily in index and mixed funds [1] - The highest return fund managed by Zhang is the Invesco Great Wall Nasdaq Technology ETF Link (QDII) A, which has achieved a return of 113.78% over 2 years and 156 days [1] - New fund manager Li Wenbin from Yongying Fund manages assets of 1.479 billion yuan, focusing on mixed and bond funds, with the highest return fund being the Wanji Zhizao Advantage Mixed A, which has returned 126.91% over 5 years and 165 days [1] Group 3 - In the past month, Bosera Fund conducted the most company research, engaging with 40 companies, followed by Harvest Fund with 38, Huaxia Fund with 37, and Fortune Fund with 34 [1] - The automotive parts industry was the most researched sector with 134 inquiries, followed closely by the semiconductor industry with 132 [1] - The most researched individual stock was Lexin Technology, with 95 fund management companies participating in the research [1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 CAR-T 细胞疗法 在 B 细胞恶性肿瘤中取得了令人瞩目的治疗效果，然而，其在占据癌症绝大多数的 实体 瘤 中效果差强人意，且反应通常难以持久 。 阻碍 CAR-T 细胞对实体瘤疗效的一个主要挑战是 CAR-T 细 胞对实体瘤的浸润渗透能力差。 2025 年 6 月 18 日，上海交通大学 杨选明 教授团队在 Science 子刊 Science Translation Medicine 上 发表了题为： OX40-heparan sulfate binding facilitates CAR-T cell penetration into solid tumors in mice 的研究论文。 该研究发现， 通过并联共刺激受体 OX40 的方式，能够显著增强 CAR-T 细胞对实体肿瘤 （包括 胰腺 癌、乳腺癌和肺癌 ） 的抗肿瘤活性， 这种增强作用既依赖于 OX40 配体 （OX40L） ，也独立于 OX40L。此外，该研究还发现， 硫酸乙酰肝素 （ Heparan Sulfate，HS ） 是 OX40 配体，可促进 CAR-T 细胞在实体瘤中的浸润和持久存在。 ...

9[Table_Title] 每日复盘 证券研究报告 2025 年 6 月 9 日 2025 年 6 月 9 日创业板指涨逾 1%，创新药概念股再度大 涨 报告要点： 2025 年 6 月 9 日创业板指涨逾 1%，创新药概念股再度大涨。上证指数上 涨 0.43%，深证成指上涨 0.65%，创业板指上涨 1.07%。市场成交额 12862.25 亿元，较上一交易日增加 1343.83 亿元。全市场 4171 只个股上涨，1112 只 个股下跌。 风格上看，各指数涨跌幅排序为：成长>消费>金融>周期>0>稳定；中盘 成长>小盘成长>小盘价值>中盘价值>大盘价值>大盘成长；中证全指表现优 于基金重仓。 分行业看，30 个中信一级行业普遍上涨；表现相对靠前的是：医药 （2.25%），综合（2.06%），纺织服装（1.84%）；表现相对靠后的是：食品饮 料（-0.47%），家电（-0.01%），汽车（-0.01%）。概念板块方面，多数概念 板块上涨，肝素、噪声防治、昨日连板等大幅上涨；刀片电池、托育服务、 麒麟电池等板块走低。 资金筹码方面，主力资金 6 月 9 日净流入 11.95 亿元。其中超大单净流 入 64. ...

Group 1 - The global exoskeleton robot market is entering a rapid growth phase, with a projected market size of $1.8 billion in 2024 and expected to exceed $12 billion by 2030, reflecting a compound annual growth rate (CAGR) of 28% [1] - China's 14th Five-Year Plan includes exoskeletons as a key development area for high-end medical equipment, with several regions incorporating rehabilitation exoskeletons into insurance reimbursement, which is expected to accelerate commercialization [1] - The medical rehabilitation sector is seeing mature commercialization scenarios supported by policies, with a focus on three main directions: hospital policy support (innovative drugs and devices), expanding public demand (blood products, home medical devices, weight loss drug supply chain), and an upward trend in overseas market cycles (heparin, respiratory joint inspection) [1] Group 2 - The Medical ETF (159828) tracks the CSI Medical Index (code: 399989), which is compiled by the China Securities Index Co., selecting listed companies in the medical device, medical services, and pharmaceutical commercial sectors to reflect the overall performance of related securities [1] - The CSI Medical Index has strong industry representation, with the latest trading day showing an increase of 0.95%, serving as an important reference for investors looking to allocate in the healthcare industry [1] - Investors without stock accounts can consider the Guotai CSI Medical ETF Connect A (012634) and Guotai CSI Medical ETF Connect C (012635) [1]